Mr Lewis Cameron
Avillion was registered in London UK in December 2012 and we are fully financed by the venture capital groups Abingworth and Clarus ventues. We are a company focused on co-development and financing of late-stage programs, where we provide partners with 100% financing for regulatory approval studies with the intent of accelerating the approval of drugs in the US and the EU.
We offer partners an unique and attractive option for the advancement of their pipeline- where we incur 100% of the clinical and regulatory risk of a program, thereby enabling partners to limit their P&L burden and have an advantageous financial position (EPS preservation).
Dr Andrew Carnegie
Epistem is a biotechnology company with a specialist understanding of epithelial tissue and stem cell analyses, operating three distinct business divisions.
The Contract Research Division delivers innovative preclinical research services in the areas of oncology (inc. leukaemia), mucositis, inflammatory bowel disease, rheumatoid arthritis, wound healing and skincare. Working with over 200 pharmaceutical, biotechnology, and personal care companies worldwide, it offers proprietary assays for target validation, screening, efficacy, and translational biology using some of the latest technology, including small animal imaging, and with a GCLP accredited histology suite.
The Personalised Medicine Division is committed to facilitating a more tailored approach to patient treatment and care. It applies innovative gene expression technology to discovering novel drug-induced biomarkers to GCLP standard. It has also developed Genedrive™, a ‘point of care’ molecular diagnostic device providing a ‘near patient’ diagnosis in less than 30 minutes using hand held apparatus.
Our Novel Therapies Division is identifying the key regulators (proteins and peptides) of epithelial stem cells with the aim of developing therapeutics to control cell production.
Epistem LtdBusiness Development Manager
Mr Alastair Carrington
Established in 1989, the BIA (BioIndustry Association) exists to encourage and promote a financially sound and thriving bioscience sector within the UK economy and concentrates its efforts on emerging enterprise and the related interests of companies with whom such enterprise trades.
With over 300 members, the BIA supports a wide range of sectors, majoring on the human health benefits of the technology and represents the interests of these innovative companies to a broad section of stakeholders from patient groups to politicians, advancing its members interests both within the UK and internationally to create a healthy UK bioscience sector which benefits society.
BioIndustry Association (BIA)Business Development Executive
Mr Kieran Casey
Founded as Clinical Development & Support Services Ltd (CDSS) in 1998, Illingworth Research is a Clinical Research Organisation (CRO) providing a wide range of clinical development services to the pharmaceutical, healthcare, biotechnology and medical device industries. We are experts in the management of Phase I to IV clinical trials across many different therapeutic areas.
From our base in Cheshire UK, where we are co-located with our sister company ResearchNurses.co, we offer the ultimate clinical research outsourcing partnership for sponsors across the globe.
We have worked with all types of clients, from start-up biotechnology companies to large international pharmaceutical companies, providing strong sponsor/CRO partnerships to deliver a competitive advantage.
Illingworth ResearchDirector Business Development
Dr Paul Clewlow
Sygnature Discovery, founded in 2004 in Nottingham, UK, is a leading provider of integrated drug discovery services to pharmaceutical companies, biotechs and academics located in Europe and the USA. Through its unique ‘federated’ CRO model, Sygnature undertakes complete drug discovery programmes and hit finding, hit-to-lead and lead optimisation projects for its clients. The company employs 75 laboratory-based, industry-experienced PhD medicinal chemists, computational chemists and in vitro biologists.
Working within the highly-complex, competitive and fast-paced pharmaceutical and biotech sectors, Sygnature has developed a unique approach to offering a premium integrated drug discovery service – the delivery of in-depth, pharmaceutical industry-derived drug discovery expertise and flexible FTE-based resource housed in a ‘state-of-the-art’ R&D facility, but at a cost effective price. From the outset, Sygnature has operated a business whose primary focus has been value creation for its clients, through the application of drug discovery expertise, close working relationships and complete transparency.
To facilitate the delivery of top quality drug discovery services to its clients, Sygnature has strategic alliances with Cyprotex Discovery (ADME/toxicology), Saretius (pre-clinical pain/CNS and metabolic disease models), Pneumolabs (pre-clinical respiratory models), Horizon Discovery (X-ManTM isogenic cell lines), ChanTest (ion channel experts) and Proteros (X-ray protein structure analysis).
For more information, visit: www.sygnaturediscovery.com and www.integrateddrugdiscovery.com.
Ms Andrea Cotton-Berry
Ockham provides high-quality, global clinical research and strategic development services to pharmaceutical and biotechnology companies, assisting them in the achievement of their strategic planning, technology transfer, licensing, regulatory planning and submissions, pre-clinical development, and manufacturing goals.
Ockham also provides fully integrated clinical trials support in the areas of Clinical Operations, Data Management and Biostatistics, as well as Regulatory dossier compilations. In addition, it offers functional and specialty resourcing services to pharmaceutical, biotech and medical device companies that require Clinical Operations, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), or Good Manufacturing Practice (GMP) auditing, Data Management, Statistical Programming, Biostatistics, and Medical Writing solutions.